To view abstracts from the 1st, 2nd and 3rd place winners click here.
1. Vaccine wastage: An important determinant of the optimal pneumococcal vaccine vial size presentation.
Divya Parmar, Elaine Baruwa, Souleymane Kone, Patrick Zuber, Angeline Nanni
2. Anti-capsular serum antibody concentration and protection against pneumococcal colonization induced by 7-valent conjugate pneumococcal vaccine.
Millar EV, O’Brien KL, Bronsdon MA, Madore D, Hackell J, Reid R, Santosham M
3. Estimating the value of pneumococcal conjugate vaccines for improving the health of HIV exposed children in PEPFAR focus countries.
Chuka Anude, Maria Knoll, Katherine L. O’Brien, Orin S. Levine
4. Pneumococcal serotype-specific disease epidemiology: Implications for vaccine formulations and potential public health impact.
Maria Deloria-Knoll, Hope L. Johnson, Orin Levine, Laura Freimanis, Richard Reithinger, Larry Muenz, Kate O’Brien
5. Near elimination of vaccine-type pneumococcal carriage by pneumococcal conjugate vaccine in a community at high risk of carriage and disease.
Millar EV, O’Brien KL, Scott, JR, Jackson D, Whitney CG, Reid R, Santosham M and the American Indian LTNP Study Group
6. Modeling the potential impact of pneumococcal conjugate vaccine on mortality in a rural district in Kenya.
Moïsi JC, Gatakaa H, Jefwa MK, Nyundo C, Ndiritu M, Levine OS and Scott JAG
7. Replacement invasive pneumococcal disease 9 years after introduction of PCV use among a population at high risk for IPD: the Navajo experience.
O’Brien KL, Weatherholtz R, Millar EV, Watt JP, Reid R, Parkinson A, Santosham M
8. Potential effect of secular trends in serotype-specific invasive pneumococcal disease on pneumococcal conjugate vaccine impact assessments: an exploratory analysis.
Perilla MJ, Millar EV, Weatherholtz R, Reid R, Santosham M, O’Brien KL
9. Phase I clinical trial of a live attenuated H7N3 influenza virus vaccine.
Kawsar Talaat, Ruth Karron, Karen Callahan, Catherine Luke, Bhagvanji Thumar, Grace Chen, Elaine Lamirande, Hong Jin, Kathy Coelingh, George Kemble, Kanta Subbarao
10. The length and amino acid composition of sequences added to the carboxy terminus of the influenza A virus M2 protein have differential effects on virus replication and virulence.
Wai-Hong Wu, and Andrew Pekosz
11. Dynamics of transplacental transfer of maternal dengue antibodies among mothers and infants in Bangkok.
Willem G. van Panhuis and Anna P. Durbin
12. Safety and efficacy of Motavizumab in the prevention of RSV disease in healthy infants.
Chandran A; Millar E; Weatherholtz R; Campbell J; Perilla M; Moulton L; Reid R; Harris B; Connor E; Losonsky GA; Griffin MP; Karron R; Santosham M; O’Brien KL and the RSV Prevention Study Team
13. Comparison of “antibody in lymphocyte supernatant” (ALS) and ELISPOT assays for indirect detection of mucosal immune responses to Shigella LPS in clinical specimens.
Andrea M. Jones, Robin McKenzie, David N. Taylor, Colleen M. Carpenter Shannon L. Grahek, Malabi M. Venkatesan, Thomas L. Hale, August L. Bourgeois
14. Adenovirus virions that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce neutralizing antibodies in mice.
Christopher Palma, Michael Overstreet, Jean-Marc Guedon, Egbert Hoiczk, Fidel Zavala, and Gary Ketner
15. SOCS-1 silencing in measles virus primed dendritic cells enhances presentation of measles virus and other (influenza virus) antigens.
Zaza Ndhlovu and Diane E Griffin
16. Effects of exogenous estrogen & progesterone on the natural history of the human papillomavirus: Implications for vaccine induced immunogenicity & long-term efficacy.
Marks M., Gravitt P. , Celentano D. , Klein,S.
17. Streptococcus Pneumoniae meningitis surveillance in children under five years of age in Santo Domingo, Dominican Republic.
Feris J, Coradin H, Gilani Z, Sanchez J, Floren A, Peynado M, del Moral T, Pena C, Fernandex J, Deloria-Knoll, M, Perez-Then E
18. Hib and SP Meningitis CFR by WHO Region and Mortality Strata.
Gilani Z, Deloria-Knoll M, O'Brien KL, Wolfson LJ, Watt JP, Henkle E, McCall N, Lee E, Mulholland K, Levine O, Cherian T for the Hib and Pneumococcal Global Disease Burden Study Team
19. Two Phase I Studies to Investigate the Immunogenicity & Safety of Different Formulations of a Novel Vaccine Against Staphylococcus aureus (V710)
Clayton Harro, Robert Betts, Joy Lipka, Jon Hartzel, Matthew Onorato, Nicholas Kartsonis
20. A Phase I, Dose-ranging Study to Evaluate the Immunogenicity and Safety of a Novel Vaccine Against Staphylococcus aureus (V710)
Clayton Harro, Robert Betts, Walter Orenstein, Eun-Jeong Kwak, Howard Greenberg, Larry Padget, Matthew Onorato, Jon Hartzel, Joy Lipka, Nicholas Kartsonis
21. Age Distribution of Sp and Hib Meningitis Cases: The Hib and SP Global Disease Burden Project.
Henkle E, Cherian T, Knoll M, Levine OS, Mulholland K, Watt JP, Wolfson L and O’Brien KL, for the Hib and SP GDB Study Team
22. Understanding poor CD8+ T cell responses to peptide-based vaccination.
Michael G. Overstreet, Helen Freyberger, Fidel Zavala
23. Developing an Effective DNA-based Vaccine against Malaria.
Hong Zhang, Michael Overstreet, Janet Tai, Timothy M. Alce , Arya Biragyn, Fidel Zavala, Richard Markham
24. Conjugated Peptide Vaccine is able to Prevent and Treat Experimental Autoimmune Myocarditis by Altering Trafficking of Autoaggressive Cells to the Heart.
D Cihakova, JG Barin, M Kimura, GC Baldeviano, MV Talor, DH Zimmerman, E Talor, NR Rose
25. Country and Regional Representation of Meningitis Incidence Data for Hib and Spn Global Disease Burden Estimates.
Knoll MD, Henkle EM, Grant LR, Wolfson LJ, Watt JP, O’Brien KL, Mulholland K, Levine OS, Cherian T, for the Hib and Spn Global Disease Burden Study Team
26. Costs and cost-effectiveness of immunisation programmes: the role of lay health workers.
Adrijana Corluka, Damian G. Walker, Simon Lewin, Inger Scheel, Claire Glenton, Marit Johansson
27. The value of vaccination: Examining the long-term economic consequences of vaccines.
Julia Driessen, Abdur Razzaque, Damian Walker, David Canning
28. Idiopathic Acute Transverse Myelitis, comparison of patients with vs. without receipt of a vaccine within 30 days prior to onset.
Yandong Qiang, Chitra Krishnan, Douglas Kerr, Rosanna Setse, Megan Quigg, Neal A. Halsey
29. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
Mlambo G, Maciel J, Kumar N.
30. Memory CD8+ T Cell Responses Expand When Antigen Presentation Overcomes T Cell Self-Regulation.
Ian A. Cockburn, Sumana Chakravarty, Michael G. Overstreet, and Fidel Zavala
31. The art of modeling vaccine decision making: an interdisciplinary approach.
Meghan Stack and Marcie Richmond
32. Influenza vaccine effectiveness during the 2006-7 season in HIV-infected and -uninfected women: Nested studies in the Women’s Interagency HIV Study (WIHS)
Keri N. Althoff, Maryna Eichelberger, Jin Gao, Stephen J. Gange
33. The 1918 Influenza Pandemic Experience in Japan: Age and Geographic Mortality Patterns
S. A. Richard, N. Sugaya, L. Simonsen, M. A. Miller, C. Viboud
34. Acceptability Survey of HPV Vaccine Among Female Sex Workers in Lima, Peru.
Brandon Brown, Neal Halsey, Cesar Carcamo, Maria Valderrama, and Magaly Blas
35. Comparison of the T Cell Responses to Live Attenuated Measles Vaccine Delivered to Rhesus Macaques by Inhalation and by Subcutaneous Inoculation.
Wen-Hsuan Lin, Robert Sievers and Diane E. Griffin
36. Markedly Enhanced Immunogenicity of a Pfs25 DNA-Based Malaria Transmission- Blocking Vaccine by In Vivo Electroporation.
Ralph LeBlanc, Yessika Vasquez, Drew Hannaman and Nirbhay Kumar
37. Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan Infants by Ethnic Group and Nutritional Status.
EJ Asturias, C Mayorga, P Ramirez, M Ram, T Verstraeten, R Clemens, N Halsey
38. Sporozoite-Kupffer cell interactions determine Plasmodium berghei infection of the mouse liver: screening for a new liver-stage malaria vaccine candidates.
Cha SJ, Stins M, Gosh A, Jacobs-Lorena M
39. The adjuvant effect of infection: complement receptors 1/2 regulate alternatively activated macrophages following coxsackievirus B3 infection.
Sylvia Frisancho-Kiss, J. Augusto Frisancho, Michael J. Coronado, D. Bedja, K. Gabrielson, Jaewook Shin, Daniela Cihakova, Noel R. Rose and DeLisa Fairweather
40. Monitoring adverse events following yellow fever vaccination using an integrated telephone and internet-based system.
Anna P. Durbin, Rosanna Setse, Saad B. Omer, James G. Palmer, Jeffrey A. Spaeder, Judy Baker, Frances Lessons, and Neal A. Halsey
41. Sex Differences in Response to Influenza: Implications for Vaccination
Dionne P. Robinson, Jenifer B. Kaplan, and Sabra L. Klein
42. Communication and Advocacy for Accelerated Introduction of Hib Vaccine.
Judy Heck, Rose Reis, Diane Coraggio, Lois Privor-Dumm
43. Whole genome sequence analysis of human AU-1-like rotavirus isolates with mixed genotypes from a Brazilian outbreak.
Kaitlin R. Lovett, Takeshi Tsugawa, and Yasutaka Hoshino
44. Alternatives to Optical Microscopy to Monitor Malaria Vaccine Efficacy.
Abhai Tripathi, John Pisciotta, Peter Scholl, Sunil Sazawal, Plamen Demeriev, Andew Feldman, Nirbhay Kumar and David Sullivan
45. Imbalance in Immune Priming against Neutralizing and Non-Neutralizing Measles Virus Epitopes after Immunization with an Inactivated Vaccine
M. Jeff Bergen, Chien-Hsiung Pan and Diane E. Griffin
46. Risk of Pertussis Associated With Geographic Clusters of Non-Medical Exemptions in the United States: Evidence from Two Large States.
Saad B. Omer, Lawrence H. Moulton, Timothy J. Dube, Stephanie Schauer, Shannon Stokley, Tracy N. LaPorte, Michael Pierce, Howard Backer, Neal A. Halsey, Daniel A. Salmon
47. Strategic communications drives an increase in visibility of pneumococcal disease worldwide
Kvist H, Levine O S, Moncrieffe Foreman M, Kim H B, Buss J, Haylock S